Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Growth in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the target of a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 21,284 shares, an increase of 62.6% from the July 15th total of 13,090 shares. Approximately 5.3% of the shares of the stock are short sold. Based on an average daily volume of 111,194 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

Silexion Therapeutics Trading Down 4.1%

SLXN stock traded down $0.02 during trading on Monday, reaching $0.40. 136,297 shares of the stock were exchanged, compared to its average volume of 327,408. The business has a 50 day moving average price of $2.42 and a 200-day moving average price of $8.52. Silexion Therapeutics has a 1 year low of $0.37 and a 1 year high of $80.00. The firm has a market capitalization of $346,580.00, a price-to-earnings ratio of -0.01 and a beta of -0.25.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Friday, August 14th. The company reported ($5.17) earnings per share for the quarter, beating the consensus estimate of ($21.20) by $16.03. On average, research analysts anticipate that Silexion Therapeutics will post -45.5 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Silexion Therapeutics stock. Ancora Advisors LLC bought a new stake in Silexion Therapeutics Corp (NASDAQ:SLXN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 30,000 shares of the company’s stock, valued at approximately $31,000. Ancora Advisors LLC owned 7.14% of Silexion Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 10.95% of the company’s stock.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.